COMPASS Pathways Plc – American
$6.75
Stock Quotes & Analysis
CMPS3.53%
$6.75
Latest AAPL News (Need to figure out how to make this dynamic)
test
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
COMPASS Pathways Plc - AmericanStatus: Active
Sector: Healthcare
Industry: Medical Care Facilities
Symbol: CMPS
Exchange: NMS
Employees: 166
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
 | 33 Broadwick Street, London, United Kingdom |
 | https://compasspathways.com |